Dexcom (DXCM) Capital Expenditures (2010 - 2026)

Dexcom (DXCM) has 17 years of Capital Expenditures data on file, last reported at $76.6 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 11.95% year-over-year to $76.6 million in Q1 2026; TTM through Mar 2026 was $353.1 million, a 9.21% decrease from a year earlier, with the FY2025 full-year figure at $363.5 million, up 1.31% from the prior year.
• Capital Expenditures for Q1 2026 stood at $76.6 million, down from $101.9 million in the prior quarter.
• Over the last five years, Capital Expenditures for DXCM reached as high as $124.6 million in Q4 2024 and fell as low as $50.4 million in Q3 2023.
• Historically, Capital Expenditures has averaged $82.4 million across 5 years, with a median of $80.5 million in 2025.
• Across the five-year window, Capital Expenditures sank 53.42% in 2023 and jumped 137.33% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $63.5 million in 2022, then declined by 17.32% to $52.5 million in 2023, then soared by 137.33% to $124.6 million in 2024, then retreated by 18.22% to $101.9 million in 2025, then retreated by 24.83% to $76.6 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $76.6 million in Q1 2026, $101.9 million in Q4 2025, and $80.5 million in Q3 2025.